secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001193125-24-157374
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma shareholders approve all proposals at 2024 AGM
------------------------------------------------------------------

- Quorum of 57.6M shares (64% of eligible) voted; all seven proposals passed.
- Proposal 6 (reappointment of Louis Lange): 34.5M For, 13.2M Against, 357k Abstain.
- Proposal 5 (appointment of William H. Lewis): 48.1M For, 10.7k Against, 1.2k Abstain.
- Adopted 2023 annual accounts, discharged directors, ratified Deloitte as auditor for 2024.
- Item 8.01 refiled a license agreement with Menarini omitted from 2023 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524157374/0001193125-24-157374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524157374/d837571d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-157374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer